Mevo Health Review
Best for: Patients wanting a physician-network-led compounded GLP-1 plan with both injection and oral-tablet options for both semaglutide and tirzepatide, on monthly/quarterly/six-month flexibility. Best for buyers who do not require a published per-state availability list or named pharmacy partner upfront.
Mevo Health (mevohealth.com) is a Delaware-LLC direct-pay telehealth platform offering compounded semaglutide and compounded tirzepatide in both injection and oral-tablet forms. Verbatim pricing positioning: semaglutide ‘as low as $199/month’, tirzepatide ‘as low as $259/month’, with monthly, quarterly, and six-month plan options. The site displays a LegitScript approval seal and the verbatim FDA disclaimer ‘The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.’ Care is delivered by licensed physicians through the Mevo medical network; four named board-certified physicians: Dr. David Wasef (head of the Mevo Provider Network), Dr. Frank Suppa, Dr. Andrew Sakla, Dr. Constantin Chikando. Pharmacy fulfillment is described as ‘503A U.S. compounding pharmacies’ — two pharmacy logos shown on site but partner names are not surfaced in text. States served are not enumerated publicly. No insurance accepted (direct-pay). Operating entity: Mevo Health LLC, governed by Delaware law. WLR clinical-network disclosure (2026-05-24): Dr. David Wasef and Dr. Frank Suppa also appear on Vytora Health and Ondra Health — multi-platform physician-network pattern; Mevo Health LLC is a distinct Delaware corporate entity. Live-verified 2026-05-24.
Medium confidence · Last verified 2026-05-24 via Eli Marsden · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Mevo Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Mevo Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Entry price (all doses) | compounded | $199 |
| Entry price (all doses) | compounded | $259 |
✓ Pros
- •**LegitScript verification badge** present on multiple site pages
- •**Verbatim FDA compounded-medication disclaimer** present (transparency win)
- •**Four named board-certified physicians** disclosed (Wasef, Suppa, Sakla, Chikando)
- •**Both molecules in both routes** offered (sema + tirz in injection AND oral tablet) — rare in DTC space
- •Public pricing surfaced (entry-price ‘as low as’)
- •Plan flexibility (monthly / quarterly / six-month)
- •Operating entity disclosed (Mevo Health LLC, Delaware)
✗ Cons
- •**States served not enumerated** on any public page (homepage, contact, terms, privacy)
- •**Pharmacy partners not named** — only described as ‘503A U.S. compounding pharmacies’ with two unlabeled logos
- •**No Medical Director named by title** — Dr. David Wasef is ‘head of the Mevo Provider Network’ but no formal Medical Director role disclosed
- •**Pricing is ‘as low as’ floor only** — per-dose itemization not surfaced publicly
- •No SOC 2 certification claimed
- •Footer typo: ‘HIPPA Policy’ link text
- •Clinical-services-PC overlap with Wasef Health PC pattern (Vytora, Ondra, Cora, Refills, sermorelin.com) — not a duplicate brand but worth disclosing
Ready to start with Mevo Health?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our Mevo Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Mevo Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Mevo Health?
Starting at $199/month. See current pricing and start your free consultation.